Inarigivir soproxil, also known as SB 9200, is an antiviral agent. SB 9200 is also a novel agonist of innate immunity, which shows potent antiviral activity against resistant HCV variants. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus, and influenza and has demonstrated activity against hepatitis B virus (HBV) in vitro and in vivo. In phase I clinical trials in chronically infected HCV patients, SB 9200 has been shown to reduce HCV RNA by up to 1.9 log10 .
Chemical Properties:
density: 1.80±0.1 g/cm3(Predicted)
pka: 9.39±0.10(Predicted)